A new study has found an unexpected new drug target for acute myeloid leukemia that could open new avenues to develop effective treatments against this potentially lethal disease. Researchers show that inhibiting the METTL3 gene destroys AML cells without harming non-leukemic blood cells and reveals why METTL3 is required for AML cell survival.